Early virological failure after tenofovir + didanosine + efavirenz combination in HIV-positive patients upon starting antiretroviral therapy

Antiviral Therapy

Volumn 10, Issue 4, 2005, Pages 505-513

  Torti, Carlo ^a   Quiros Roldan, Eugenia ^a   Regazzi, Mario ^b   Antinori, Andrea ^c   Patroni, Andrea ^a,b   Villani, Paola ^b   Tirelli, Valeria ^a   Cologni, Giuliana ^a   Zinzi, Daniela ^c   Lo Caputo, Sergio ^d   Perini, Paolo ^e   Carosi, Giampiero ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^d SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^e A MANZONI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; RNA DIRECTED DNA POLYMERASE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ADULT; AMINO ACID SUBSTITUTION; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC POLYMORPHISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; LYMPHOCYTE COUNT; MALE; MOLECULAR EVOLUTION; NONHUMAN; PATIENT COMPLIANCE; PHARMACOGENETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; TREATMENT FAILURE; VIRUS DETECTION;

ADULT; ANTI-HIV AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; PATIENT COMPLIANCE;

EID: 23044439348     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Polis MA, Sidorov IA, Yoder C, Jankelevich S, Metcalf J, Mueller BU, Dimitrov MA, Pizzo P, Yarchoan R & Dimitrov DS. Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy. Lancet 2001; 358:1760-1765.
2. Whitcomb JM, Parkin NT, Chappey C, Hellmann NS & Petropoulos CJ. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. Journal of Infectious Diseases 2003; 188:992-1000.
3. Kempf DJ, King MS, Bernstein B, Cernohous P, Bauer E, Moseley J, Gu K, Hsu A, Brun S & Sun E. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. Journal of Infectious Diseases 2004; 189:51-60.
4. Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, Johnson M, Johnson D, Lalonde R, Japour A, Brun S & Sun E; M98-863 Study Team. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. New England Journal of Medicine 2002; 346:2039-2046.
5. Keil K, Frerichs VA, DiFrancesco R & Morse G. Reverse phase high-performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite (M8), ritonavir and saquinavir in heparinized human plasma. Therapeutic Drug Monitoring 2003; 25:340-346.
6. Johnson VA, Brun-Vezinet F, Clotet B, Conway B, D'Aquila RT, Demeter EM, Kuritzkes DR, Pillay D, Schapiro JM, Telenti A & Richman DD. Update of the drug resistance mutations in HIV-1: 2004. Topics in HIV Medicine 2004; 12:119-124.
7. Clotet B, Menendez-Arias E, Schapiro E, Ruiz E, Kuritzkes D, Bruger D, Tural C, Brun-Vezinet F, Loveday C, Boucher D'Aquila R & Richman D. Guide to Management of HIV Drug Resistance, Antiretrovirals Pharmacokinetics and Viral Hepatitis in HIV Infected Subjects. Fourth edition 2004. Fundaciò de Lluita contra la SIDA Hospital Universitari 'Germans Trias I Pujol', Badalona, Catalonia, Spain: Ediciones Graficas Rey, S.L.
8. Podzamczer D, Ferrer E, Gatell JM, Nuibo J, Dalmau D, Leon A, Knobel H, Iniguez D & Ruiz I. Early virologic failure with a combination of tenofovir, didanosine and efavirenz. Antiviral Therapy 2004; 9:S172.
9. 3 receiving didanosine (ddl)/tenofovir (TDF)/efavirenz (EFV): 12 week results from a randomized comparative trial. 7th International Congress on Drug Therapy in HIV Infection. 14-18 November 2004, Glasgow, UK. Abstract PL2.5.
10. McColl DJ, Margot NA, Wulfsohn M, Coakley DF, Cheng AK & Miller MD. Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate. Journal of Acquired Immune Deficiency Syndromes 2004; 37:1340-1350.
11. Boffito M, Bonora S, Sinicco A, Raiteri R, Milia MG, Khoo SH, Hoggard PG, Back DJ & Di Perri G. Treating advanced HIV infection. Journal of Acquired Immune Deficiency Syndromes 2003; 34:344-345.
12. Gathe JC, Washington MY, Mayberry C, Piot D & Nemecek J. IMANI-1 TC3WP single drug HAART - proof of concept study. Pilot study of the safety and efficacy of Kaletra (LPV/r) as single drug HAART in HIV+ ARV-naive patients-interim analysis of subjects completing final 48 week data. 15th International AIDS Conference. 11-16 July 2004, Bangkok, Thailand. Abstract MoOrB1057.
13. Winston A, Pozniak A, Mandalia S, Gazzard B, Pillay D & Nelson M. Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase. AIDS 2004; 18:949-951.
14. Valer L, Martin-Carbonero L, De Mendoza C, Corral A & Soriano V. Predictors of selection of K65R: tenofovir use and lack of thymidine analogue mutations. AIDS 2004; 18:2094-2096.
15. Segondy M & Montes B. Prevalence and conditions of selection of the K65R mutation in the reverse transcriptase gene of HIV-1. Journal of Acquired Immune Deficiency Syndromes 2005; 38:110-111.
16. White KL, Margot NA, Wrin T, Petropoulos CJ, Miller MD & Naeger LK. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity. Antimicrobial Agents & Chemotherapy 2002; 46:3437-3446.
17. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ & Cheng AK; 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. Journal of the American Medical Association 2004; 292:191-201.
18. Molina JM, Peytavin G, Perusat S, Lascoux-Combes C, Sereni D, Rozenbaum W & Chene G. Pharmacokinetics of emtricitabine, didanosine and efavirenz administered once-daily for the treatment of HIV-infected adults (pharmacokinetic substudy of the ANRS 091 trial). HIV Medicine 2004; 5:99-104.
19. Bristol-Myers Squibb (BMS). Important new clinical data: potential early virologic failure associated with the combination antiretroviral regimen of tenofovir disoproxil fumarate, didanosine, and either efavirenz or nevirapine in HIV-treatment naive patients with high baseline viral loads. 'Dear Healthcare Provider' letter 2004, issued in the US.